Zobrazeno 1 - 10 of 21 pro vyhledávání: '"C F Pollera"'
1
Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome
Autor: Diana Giannarelli, Fabrizio Nelli, Luca Moscetti, Isabella Sperduti, D. Padalino, C. F. Pollera
Publikováno v: Scopus-Elsevier
ResearcherID
The aim of the study was to describe in detail the impact of aging and comorbidities on safety and efficacy of gemcitabine-cisplatin in the subset of elderly with advanced NSCLC. We report the results of our study which enrolled patients aged over 65
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2155fdd29d98b33a4bbb479de47ef01
https://doi.org/10.1179/joc.2005.17.6.685
Zobrazit plný text záznamu
2
Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer
Autor: Francesco Cognetti, Anna Ceribelli, Alain Gelibter, Michele Milella, C. F. Pollera, Isabella Sperduti, Luca Moscetti
Publikováno v: Journal of Cancer Research and Clinical Oncology. 131:783-788
Purpose: Patients with advanced non-small-cell lung cancer (NSCLC) have a short life expectancy; therefore, in addition to increasing their survival, improving their quality of life (QoL) is also an important treatment goal. Methods: We evaluated the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9524fa62db1da28dddd51675fbd565a2
https://doi.org/10.1007/s00432-005-0029-9
Zobrazit plný text záznamu
4
A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin
Autor: L, Moscetti, D, Padalino, E, Capomolla, F, Nelli, C F, Pollera
Publikováno v: Journal of experimentalclinical cancer research : CR. 24(1)
Anaplastic thyroid carcinoma is a rare disease with a poor prognosis. Surgery represents the curative treatment for limiting the disease. In the presence of locoregional disease, not suitable for surgery, and for metastastic disease, chemotherapy rep
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::297c24aa58872df7b878c67661e63b53
https://pubmed.ncbi.nlm.nih.gov/15943045
Zobrazit plný text záznamu
5
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study
Autor: Alain Gelibter, C. F. Pollera, Paolo Carlini, Alessandra Felici, Salvatore De Marco, Francesco Cognetti, Anna Maria Fariello, Isabella Sperduti, Enzo Maria Ruggeri, Teresa Gamucci, Ennio Adami, Luca Moscetti
Publikováno v: Scopus-Elsevier
Background: It has been demonstrated that the 3-weekly PELF regimen is superior to FAM and FAMTX in advanced gastric cancer. The aim of this multicentric phase II study was to evaluate the efficacy and tolerability of a PELF regimen, given every 2 we
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::384f8d81ae6ddca5b50f82c7d4274cbd
https://pubmed.ncbi.nlm.nih.gov/16001173
Zobrazit plný text záznamu
7
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer
Autor: V, Lorusso, C F, Pollera, M, Antimi, G, Luporini, C, Gridelli, G L, Frassineti, C, Oliva, M, Pacini, M, De Lena
Publikováno v: European journal of cancer (Oxford, England : 1990). 34(8)
The aim of this study was to evaluate the efficacy and safety of gemcitabine, a pyrimidine antimetabolite, in the treatment of advanced transitional cell carcinoma of the urinary tract. 35 patients with unresectable or metastatic transitional cell ca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4caf4db623400a8728bf428449b39658
https://pubmed.ncbi.nlm.nih.gov/9849481
Zobrazit plný text záznamu
8
Gemcitabine: safety profile unaffected by starting dose
Autor: C, Martin, C F, Pollera
Publikováno v: International journal of clinical pharmacology research. 16(1)
Gemcitabine, a novel anticancer agent, has been shown to be active in several human solid tumours, including non-small cell lung cancer and pancreatic cancer. In addition, gemcitabine has been noted to have a particularly mild safety profile for such
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::468111646a3eace73d7813b6d10a7dcb
https://pubmed.ncbi.nlm.nih.gov/9001925
Zobrazit plný text záznamu
9
Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study
Autor: Anna Ceribelli, M. Crecco, C. F. Pollera, F. Calabresi
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 5(2)
Summary Background Gemcitabine (2′2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses >800 mg/m2/week. Patients and methods The present report summarizes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec63490e234d38e009cf8747797ea19e
https://pubmed.ncbi.nlm.nih.gov/8186164
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje